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Background/aim: The Motor Function Measure (MFM-32) is a classification system for ambulant and nonambulant patients with
neuromuscular diseases (NMDs). We aimed to translate it into Turkish, culturally adapt it, and test its reliability and validity for Turkish
patients with NMDs.
Materials and methods: The translation of the 32 items assessing three functional areas: standing position and transfers (D1: 13),
axial/proximal (D2: 12), and distal (D3: 7) motor functions was performed according to the established guidelines for cross-cultural
adaptation. Totally 51 patients (12.56 ± 8.84 years; F/M 12/39) were tested. Vignos and Brooke scores for the lower and upper extremities,
respectively, were used for the validity of the MFM-32-TR items, which were rated on a 4-point Likert scale.
Results: The agreement coefficients for interrater reliability were excellent (0.72–0.93) for 10 items, good (0.58–0.77) for 16 items,
and moderate (0.42–0.56) for 6 items of the MFM-32-TR. The intertester reliability varied from good to excellent and the intraclass
correlation coefficient was 0.76–0.93. The MFM-32-TR positively correlated with Vignos and Brooke scores with coefficients 0.47 to
0.75, indicating concurrent validity.
Conclusion: The MFM-32-TR is a reliable and valid outcome measure for the assessment of motor function of people with NMDs in
our sociocultural context.
Key words: Neuromuscular diseases, motor functions, cultural adaptation, validity, reliability

1. Introduction
Neuromuscular diseases (NMDs) as a heterogenic group of
diseases affecting the muscle and nerve tissues at different
levels are clinically progressive and characterized by a variety of clinical features. Although there are different types of
diseases, which are seen due to hereditary or acquired reasons, diseases of the anterior horn motor cells, peripheral
nerves, neuromuscular conjunction, or muscle are the most
common ones (1). Unfortunately, most of them are still incurable and involve severe impairment and progressive decline of motor function (2). Therefore, physical therapy and
rehabilitation interventions and assessment techniques of
the functional performance of the patients are still noteworthy for prognosis of the diseases. This is especially important
for patients in clinical trials in order to detect their expected
* Correspondence: srpl.oan@gmail.com
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functional capacity. There is a variety of test materials to
evaluate the functional level of the patients. Some are disease
specific assessment techniques such as the Hammersmith
Motor Ability Score (3,4), which is more suitable in strong
non-ambulant patients (5), and the North Star Ambulatory
Assessment (6), which is specifically designed for ambulant
DMD boys to address the functional changes (7). Some are
designed for all types of NMDs regardless of the ambulatory
levels of the patients, such as the Brooke Upper Extremity
Functional Rating Scale (8) and the Vignos Functional Rating Scale (9), to assess the functional level of upper extremity and the ambulation level of subjects with NMDs, respectively. However, those all focus on different aspects of the
functional level of the patients and are not efficient to follow
the functional changes in patients with NMDs (10).
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2. Materials and methods
2.1. Participants
A total of 51 (12 F/39 M) patients aged 12.56 ± 8.84 years
(6–21 years; median 10 years), and diagnosed with a
NMD (Duchene muscular dystrophy (n = 25), myopathy
(n = 9), spinal muscular atrophy (n = 5), Becker muscular
dystrophy (n=5), polyneuropathy (n = 5), Friedreich ataxia
(n = 2)) were included in this study. They were diagnosed
in a neurology department by neurologists, based on the
clinical criteria of NMDs. Participants with any history
of orthopedic, rheumatologic, or vascular problems were
excluded from the study.
Before participating, all patients and the parents
of the pediatric patients read and signed the informed
consent forms. The study was approved by the Review
Board of İstanbul Faculty of Medicine, İstanbul University
(22/04/2009) and conducted in accordance with the
Helsinki Declaration.
Since the age range and median of the participants
were 6–21 years and 10 years, respectively, the MFM32 was used to perform this cross-cultural adaptation,
reliability, and validity study. The total scores and subscores
of the MFM test were determined in three motor function
domains: D1, D2, and D3 (Figure 1). The dimension of
each item was scored on a 4-point scale and noted on the
scoring sheet.
Generic scoring was defined as follows:
0: Cannot initiate the task, or cannot maintain the
starting position
1: Partially performs the task
2: Performs the movement incompletely, or completely
but imperfectly (compensatory movements, position
maintained for an insufficient duration of time, slowness,
uncontrolled movement)
3: Performs the task fully and “normally”; the movement
is controlled, mastered, directed, and performed at
constant speed.
VIGNOS Functional Rating
Scale
Assessment of Function

The Motor Function Measure (MFM) aims at
measuring the motor function of the whole body of
children and adults with NMDs for a wide spectrum
of these diseases, ranging from those with limb girdle
predominance to those with distal impairments (10). It is
a reliable and objective test and easy to apply (10,11). The
test was developed in the L’Escale Service of Paediatric Reeducation in Lyon, France, between 2000 and 2005, and it
is available in several languages (French, Dutch, English,
German, Portuguese, and Spanish). This scale has been
adapted to patients who can walk as well as those with
partial or total gait impairments (12). Therefore, it allows
the monitoring of patients’ activity level and helps to assess
the impact of treatments (10), and to predict the loss of
walk for patients with DMD (11). MFM-20 is used for
children under 6 years of age, while the MFM-32 is used
for evaluating a wide range of patients between the ages of
6 and 60 years.
The scale includes 32 items for adults and 20 items for
children in three motor function domains: D1 standing
position and transfers, D2 axial and proximal motor function, and D3 distal motor function (10,13). In these dimensions, a unique approach to the functional level of the
patients with NMDs is followed, which may be the main
cause of the interest from researchers and clinicians in the
MFM. It is aimed to search what the patients with NMDs
can do, instead of what they cannot do. That provides an
inclusive assessment of body functions and gives a taste
of success even though they might have very limited joint
movements due to the severity of the prognosis. A simple
or easy motion such as turning the head to the right or
left may be the only motion that the patient can do successfully, or a complicated and functional movement such
as collecting the coins on a table may be among the motions that the patient can perform successfully even if she/
he cannot walk or stand independently. Therefore, as Vuillerot et al. (14) stated, MFM defines the functional level of
the patients with NMDs, regardless of the level of disease
severity. It provides information on the motor function of
the lower extremity, trunk, and upper extremity, and especially on proximal control (pelvis and shoulder) and distal
control (hands and feet) of the extremities. We think that
a Turkish translation and cultural adaptation of the MFM
will meet the requirements of a detailed and accurate assessment technique for professionals dealing with NMDs,
as well as contribute to the subject-related literature in
Turkish.
Therefore, the aim of this study was to translate and
culturally adapt the MFM-32 into Turkish, and to investigate its test/retest reliability, intertester reliability, and construct validity in patients with NMDs.

BROOKE Functional Rating
Scale
MFM
Standing Position & Transfers
D1 (n = 13)
Axial & Proximal Motor Funct.
D2 (n = 12)
Distal Motor Function
D3 (n = 7)

Figure 1. The motor function assessment tests applied to the
participants.
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The scores were expressed as percentages in relation
to the maximum score. The total score was the sum of the
scores of 32 items ranging from 0 to 96. The total loss of
function and the loss of function in each dimension were
calculated as percent values as described in Berard et al.
(13).
We assessed the functional level of the lower
extremities by the Vignos Functional Rating Scale (9) and
the functional level of the upper extremities by the Brooke
Functional Rating Scale (8).
2.2. Translation and cross-cultural adaptation procedure
Initially, permission was obtained from the L’Escale
group to validate the Turkish version of the MFM-32.
The English version of the MFM-32 (15) was adapted for
Turkish use according to the established guidelines for
cross-cultural adaptation of self-report measures (Figure
2). In the first stage, two Turkish native speakers who

are fluent in English translated the English version of the
MFM into Turkish, independently. In the second stage,
the two translators and a team of experts combined both
translations, and formed a common draft. In the third
stage, two persons independently translated this common
draft back into English. Both translators were bilingual
native English speakers. Neither translator received any
background information on the study or on the MFM.
In the fourth stage, an expert committee consisting of the
forward and back translators and two physiotherapists
reviewed all the translations. They reached semantic,
idiomatic, experiential, and conceptual consensus on all
discrepancies. Thus, the prefinal version of the Turkish
MFM was consolidated. In the fifth stage, the prefinal
version of the Turkish MFM was tested in a group of 10
patients with NMDs for the accuracy and the explicitness
of the terminology. One of the assessors (physiotherapist)

ENGLISH VERSION of MFM- 32

FORWARD TRANSLATION
TURKISH VERSION 1

TURKISH VERSION 2

Translator 1

Translator 2

1st MEETING OF
THE CULTURAL ADAPTATION
COMMITEE
SYNTHESIS OF TRANSLATIONS

BACK TRANSLATION

ENGLISH VERSION 1

ENGLISH VERSION 2

Translator 3

Translator 4

2nd MEETING OF
THE CULTURAL ADAPTATION
COMMITEE
SYNTHESIS OF TRANSLATIONS

Evaluation of the equivalence
between the original scale
and back translations by the
CAC
TURKISH VERSION of MFM - 32
Figure 2. Flowchart of the cultural adaptation phase.
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documented the existing problems during the pilot study.
Considering these issues, the final Turkish MFM was
established.
The reliability and validity of the final Turkish version
of MFM were tested in 51 patients with a NMD. All
patients were tested with the Turkish version of the MFM
by the same assessor. All examinations were recorded on
video and each item of the scale was rated twice as test
and retests with a 5-day interval by Assessor I and Assessor
II also rated the same patient group independently from
Assessor I.
2.3. Statistical analysis
The data were analyzed using SPSS version 21.0 (SPSS Inc.,
Chicago, IL, USA). The Kolmogorov–Smirnov test was
used to assess the distribution of all scores of Assessors I
and II. It was found that the data were normally distributed.
Descriptive statistics for continuous variables were
reported as mean, median, and standard deviation and
for categorical variables were reported as frequency and
percentage. Intraclass correlation coefficients (ICCs) were
calculated to determine test/retest reliability, ICCs were
calculated to determine intertester reliability, Cronbach’s
alpha coefficient was used to assess the internal consistency
of the MFM, and Pearson’s correlation coefficient was used
to assess the validity of the Turkish version of the MFM32. Statistical significance was considered as P ≤ 0.05.
2.4. Reliability
The reliability of the MFM was evaluated by analyzing
test/retest reliability and interrater reliability. Test/retest
reliability was determined by using the assessments
completed by the physiotherapist (Assessor I) at a 5-day
interval as test and retest, and by comparing the achieved
test and retest scores. The first and second assessments
were completed in the outpatient neurology department.
Test/retest reliability was assessed using ICCs, and the
paired t-test used for reliability of the two administrations
of the questionnaire by Assessor I and Assessor II. Assessor

1 and Assessor 2 completed the evaluation on successive
days. One of the assessors had 9 years and the other had 4
years of experience in neurologic rehabilitation. The ICC
value of >0.70 indicated that the instrument was reliable
(16).
2.5. Validity
The validity of the construct was assessed by examining
correlations between the scores of the MFM-32 and the
Vignos and Brooke Functional Rating Scales. Pearson’s
correlation coefficients were used to examine the construct
validity since the MFM-32 and the Vignos and Brooke
Functional Rating Scale scores were continuous variables
and normally distributed. Correlation coefficients were
rated as follows: ≤0.40 poor, ≤0.40 to 0.75 intermediate to
good, and ≤0.75 excellent (17).
3. Results
3.1. Characteristics of the participants
The demographic and physical characteristics of the
participating patients are given in Table 1. The total scores
of patients from motor function assessments are shown in
Table 2.
3.2. Test/retest reliability and intertester reliability
The difference between test and retest measurements was
not statistically significant (P > 0.05). In other words, the
outcomes of the tests done by Assessor I 5 days apart were
similar to each other and they were reliable. The results of
reliability analyses and the mean scores of subscales are
presented in Table 3. The test/retest reliability (ICC ranged
from 0.76 to 0.90, Cronbach’s alpha ranged from 0.84 to
0.93) was excellent (18).
Interrater reliability was also excellent (0.78–0.93) for
10 items (D1: 11, 12, 30, 32; D2: 1, 2, 5, 9, 13; D3: 20),
good (0.58–0.77) for 16 items (D1: 6, 24, 25, 26, 27, 28,
29, 31; D2: 3, 7, 14, 16, 23; D3: 4, 21, 22) and moderate
(0.42–0.57) for 6 items (D1: 8; D2: 10, 15; D3: 17, 18, 19).
The interrater reliability between the outcomes of Assessor

Table 1. Sociodemographic and physical characteristics of the patients.
Characteristics
n = 51

Mean ± SD
(Median)

%

Age (years)

12.56 ± 8.84
(10)

n/a

Sex (female/male)

12/39

23.52–76.48

Weight (kg)

33.35 ± 14.17

n/a

Height (cm)

151.29 ± 105.63

n/a

Age of ambulant subjects (n = 36)

12.69 ± 10.44

70.6

Age of nonambulant subjects (n = 15)

12.26 ± 2.57

29.4

1829

İNAL et al. / Turk J Med Sci
Table 2. The total grades achieved from the tests assessing the motor function of the patients
(n = 51).
Total grade

Total loss function

Mean ± SD
(min–max)

%

Vignos Functional Rating Scale

5.03 ± 3. 32
(1–9)

n/a

Brooke Functional Rating Scale

2.58 ± 1.79
(1–6)

n/a

MFM-32 TR

59.30 ± 22.96
(0–96)

61.77

D1 (min–max: 0–39)

12.47 ± 11.2

29.24

D2 (min–max: 0–36)

28.77 ± .97

20.01

D3 (min–max: 0–21)

17.06 ± 3.20

18.78

Motor function assessment tests

Dimensions

MFM: Motor Function Measure, D1: standing position and transfers, D2: axial and proximal
motor function, D3: distal motor function
Table 3. Test/retest reliability and intertester reliability of the Turkish MFM-32.
Outcomes of Assessor I
Self-reports

Outcomes of Assessor II

Intrarater observation

Interrater observation

First–second assessments of Assessor I

Outcomes of Assessors I and II

First assessment
Mean ± SD

Second
assessment
Mean ± SD

Mean ± SD

ICC

Cronbach’s alpha

MFM total

59.30 ± 22.96

56.47 ± 31.03

54.27 ± 23.62

0.76

0.84

ICC
0.82

MFM D1

12.47 ± 11.2

12.34 ± 10.41

11.51 ± 9.24

0.77

0.87

0.93

0.96

MFM D2

28.77 ± 0.97

29.07 ± 9.31

25.56 ± 12.35

0.86

0.92

0.83

0.91

MFM D3

17.06 ± 3.20

15.06 ± 11.31

16.10 ± 2.36

0.79

0.88

0.84

0.91

Cronbach’salpha
0.74

MFM: Motor Function Measure, D1: standing position and transfers, D2: axial and proximal motor function, D3: distal motor function

I (first assessment) and Assessor II varied from good to
excellent and the ICC was between 0.76 and 0.93. This
outcome shows that the tests done by two independent
assessors are also reliable (Table 4).
3.3. Concurrent validity
To assess the validity of the MFM-32, we compared it
with the outcomes of the Vignos and Brooke Functional
Rating Scales. The MFM-32 and the Vignos and Brooke
Functional Rating Scale tests were positively correlated
with each other with coefficients ranging from 0.43 to
0.75. A moderate correlation was determined between the
MFM-32 (D1) and the Vignos Functional Rating Scale (r =
0.47; P = 0.001), and a strong correlation was determined
between the MFM-32 (D2; D3) and the Brooke Functional
Rating Scale (r = 0.75, P = 0.001; r = 0.72, P = 0.001,
respectively), indicating the concurrent validity of the
Turkish version of the MFM-32.
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4. Discussion
Patient-administered and disease-related assessment
scales examining physical function are increasingly used
in international research. As Beaton et al. (15) stated, those
instruments should be translated and cross-culturally
adapted before their use in different language speaking
populations. Therefore, the aim of the present study was
to develop a Turkish version of the MFM-32 and to verify
its inter- and intrarater reliability. As the first study to
validate the MFM-32 in a Turkish population with NMDs,
the three phases of the validation process, i.e. translation,
cultural adaptation, and reliability and validity analysis,
were fulfilled in this study.
The results of this study revealed that the reliability
and validity of the Turkish MFM-32 were satisfactory for
patients with NMD. The psychometric properties of the
Turkish MFM-32 were generally similar to those of the
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Table 4. For each item of the MFM Cronbach’s alpha (α) and intertester reliability coefficient (ICC).
Items
1

D1

D2

D3

α

ICC

α

ICC

α

ICC

-

-

0.93

0.92

-

-

2

-

-

0.91

0.93

-

-

3

-

-

0.76

0.88

-

-

4

-

-

0.77

0.88

5

-

-

0.77

0.89

-

-

6

0.68

0.78

-

-

-

-

0.67

0.77

-

7

-

-

8

0.55

0.76

-

-

9

-

-

0.72

0.81

-

-

10

-

-

0.42

0.76

-

-

11

0.82

0.89

-

-

-

-

12

0.85

0.90

-

-

-

-

13

-

-

0.91

0.89

-

-

14

-

-

0.61

0.78

-

-

15

-

-

0.56

0.76

-

-

16

-

-

0.60

0.79

-

-

17

-

-

-

-

0.56

0.76

18

-

-

-

-

0.55

0.78

19

-

-

-

-

0.42

0.76

20

-

-

-

-

0.88

0.86

21

-

-

-

-

0.76

0.89

22

-

-

-

-

0.77

0.91

23

-

-

0.73

0.84

-

-

24

0.58

0.77

-

-

-

-

25

0.66

0.82

-

-

-

-

26

0.69

0.88

-

-

-

-

27

0.71

0.90

-

-

-

-

28

0.60

0.81

-

-

-

-

29

0.66

0.87

-

-

-

-

30

0.87

0.90

-

-

-

-

31

0.76

0.88

-

-

-

-

32

0.89

0.91

-

-

-

-

D1: standing position and transfers, D2: axial and proximal motor function, D3: distal motor function

original MFM-32, which was validated by Berard et al.
(10) to measure the motor function of patients (n = 303)
with NMDs. These patients were 6–62 years old and had
Duchenne muscular dystrophy (n = 72), Becker muscular
dystrophy (n = 32), limb-girdle dystrophy (n = 30), facioscapula-humeral dystrophy (n = 39), myotonic dystrophy
(n = 29), congenital myopathy (n = 21), congenital
muscular dystrophy (n = 10), spinal muscular atrophy (n =

35), or hereditary neuropathy (n = 35). Actually, although
our sample size was smaller (n = 51) and the patients were
younger (7–21 years) than those of Berard et al.’s study
(10), the variety of the NMDs was similar as they consisted
of DMD (n = 25), myopathy (n = 9), SMA (n = 5), BMD (n
= 5), polyneuropathy (n = 5), and Friedreich ataxia (n = 5)
patients. They found that “agreement coefficients for interrater reliability were excellent for nine items, good for 20
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items and moderate for three items”. They also reported
high correlations between the total scores and the scores of
the Vignos and Brooke Functional Rating Scales. Similarly,
in our study agreement coefficients for interrater reliability
were excellent (0.75–0.93) for 9 items, good (0.58–0.77)
for 17 items, and moderate (0.42–0.56) for 6 items and
intertester reliability varied from good to excellent, since
the ICCs were strong (0.76–0.93). Therefore, we may state
that the MFM-32 was positively correlated with the Vignos
and Brooke Functional Rating Scale grades from moderate
to high with coefficients from 0.47 to 0.75, indicating
concurrent validity.
Vuillerot et al. (19) have also reported in a study
in 448 patients with genetic neuromuscular diseases that
the MFM-32 was a reliable, reproducible, and valuable
outcome measure for clinical practice and research, since
it was able to describe the physical status of patients and
formulate the uniform patient groups according to motor
function.
Iwabe et al. (12) published the Portuguese translation
of the MFM-32 and they have identified its intra and interexaminer reliability in patients with clinical and laboratory
diagnosis of various types of muscular dystrophy and
congenital myopathy. They reported a high reliability and
minimal variability as an outcome of their study, which
was similar to our intrarater outcomes.
In the light of these outcomes, we conclude that the
MFM appeared to be sensitive to capture activities and

possible changes in very weak patients. This was mainly
due to the items capturing axial and upper limb activities
in the MFM-32. According to our clinical experience, the
D2, which aims to assess the proximal control of upper
extremity with its 5 items (5 - 9 - 10 - 16 - 23) and D3, which
aims to assess fine motor function of hands with its 4 items
(1 - 18 - 19 - 20) provide detailed information to assess
proximal control with its first 3 items and hand function
with its last 3 items. Therefore, we suggest the MFM-32
for clinicians especially those aiming to determine upper
extremity function in patients with NMDs.
We may consider the wide spectrum of ages of the
patients as a limitation of this study. We could search
for the motivation of the patients and the satisfaction
level of the patients as well as the parents, which may be
recommended for future studies.
In conclusion, we may state that the Turkish version
of the MFM-32 can be used effectively as a reliable and
valid outcome measure for assessment of motor function
in patients with NMDs.
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